Takeru Wakatsuki

16PUBLICATIONS
55CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Social epidemiologyCancer geneticsMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 27, 2026
High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer.

|Apr 02, 2026
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer.

Koichiro Yoshino, Manabu Takamatsu, Akira Ooki

|Mar 15, 2026
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Takeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka

|Feb 02, 2026
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima

|Nov 05, 2025
Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC.

Kazuo Kobayashi, Takeru Wakatsuki, Erika Sugiyama

|Jul 21, 2025
Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.

Koshiro Fukuda, Hiroki Osumi, Akira Ooki

Pageof 3

Frequent Collaborators

7 joint publications

Hiroki Osumi

7 joint publications

Mariko Ogura

7 joint publications

Keisho Chin

7 joint publications

Kensei Yamaguchi